Hospital
Dignity Health
Dignity Health was paid $26.30M by Medicaid between Jan 2018 and Dec 2024, across 191 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoDIGNITY HEALTH
GLENDALE, AZ 85305
GLENDALE, AZ 85305
33aNPI1992131734assigned 09/25/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.30M
24GClaims733,435
24DCodes billed191
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#22 of 78
Median peer was paid$12.21M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 102,810 | $3.27M | |
| 2019 | 111,027 | $3.66M | |
| 2020 | 86,337 | $2.92M | |
| 2021 | 103,446 | $3.54M | |
| 2022 | 124,680 | $4.68M | |
| 2023 | 121,168 | $4.67M | |
| 2024incomplete | 83,967 | $3.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 35,708 | 32,514 | $6.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 32,597 | 30,351 | $5.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 13,857 | 12,715 | $4.67M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15% | 7,304 | 6,835 | $3.85M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.7% | 2,999 | 2,804 | $963K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 6,195 | 5,780 | $831K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 5,981 | 5,637 | $589K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.2% | 1,669 | 1,565 | $569K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.0% | 2,243 | 2,121 | $527K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 282 | 274 | $258K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 502 | 478 | $214K |
| 47562 | <1% | 70 | 65 | $198K |
179 more codes
| G0378 | Hospital observation service, per hour | <1% | 4,418 | $180K |
| 70498 | <1% | 393 | $179K | |
| 72131 | <1% | 704 | $175K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 922 | $76K |
| 93971 | <1% | 1,180 | $54K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,507 | $46K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,099 | $41K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,206 | $29K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,823 | $20K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,329 | $19K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 8,460 | $19K |
| 70496 | <1% | 459 | $16K | |
| 10060 | <1% | 66 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 748 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,901 | $7K |
| 52356 | <1% | 14 | $7K | |
| 93976 | <1% | 2,628 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,473 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,509 | $5K |
| 70486 | <1% | 199 | $5K | |
| 73130 | <1% | 1,164 | $4K | |
| 96376 | <1% | 4,235 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 38,420 | $4K |
| 76801 | <1% | 1,058 | $4K | |
| J3490 | Unclassified drugs | <1% | 16,866 | $4K |
| 88304 | <1% | 523 | $4K | |
| 73610 | <1% | 1,157 | $3K | |
| 84703 | <1% | 17,595 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,727 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,745 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,227 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,121 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,209 | $3K |
| 87040 | <1% | 4,070 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,521 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,329 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,884 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,283 | $2K |
| 93970 | <1% | 13 | $2K | |
| 87631 | <1% | 1,578 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 30 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,478 | $1K |
| 84484 | <1% | 12,626 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,101 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,639 | $1K |
| 73030 | <1% | 983 | $1K | |
| 83690 | <1% | 17,005 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,122 | $1K |
| 72100 | <1% | 630 | $951.56 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,443 | $944.34 |
| 72128 | <1% | 78 | $943.19 | |
| 81001 | <1% | 22,771 | $895.24 | |
| 73562 | <1% | 1,830 | $822.83 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,871 | $776.54 |
| 83735 | <1% | 11,404 | $693.71 | |
| 73630 | <1% | 1,421 | $692.99 | |
| 86850 | <1% | 746 | $644.78 | |
| 83605 | <1% | 10,588 | $600.49 | |
| 80329 | <1% | 1,341 | $588.08 | |
| 12001 | <1% | 65 | $558.86 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,784 | $546.10 |
| 83880 | <1% | 3,842 | $544.94 | |
| 87186 | <1% | 2,363 | $543.38 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,142 | $524.01 |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,773 | $493.09 |
| 76830 | Ultrasound, transvaginal | <1% | 977 | $461.65 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,603 | $447.28 |
| 85027 | <1% | 3,388 | $392.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,206 | $379.01 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 418 | $359.97 |
| 84702 | <1% | 2,708 | $342.93 | |
| 84439 | <1% | 546 | $338.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,089 | $323.84 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 216 | $319.84 |
| 90715 | <1% | 978 | $319.07 | |
| 81003 | <1% | 11,891 | $304.69 | |
| 85379 | <1% | 3,774 | $291.72 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,095 | $264.83 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,588 | $230.92 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,040 | $220.61 |
| 87077 | <1% | 2,739 | $201.91 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,453 | $178.34 |
| 86901 | <1% | 3,026 | $159.43 | |
| 74019 | <1% | 392 | $159.10 | |
| 86900 | <1% | 3,026 | $154.93 | |
| 82962 | <1% | 6,762 | $154.40 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 22,322 | $147.40 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,868 | $143.16 |
| 12011 | <1% | 42 | $133.42 | |
| 84145 | <1% | 1,419 | $127.60 | |
| 74018 | <1% | 1,187 | $118.17 | |
| 85610 | <1% | 4,884 | $112.75 | |
| 82550 | <1% | 2,806 | $106.46 | |
| 85730 | <1% | 2,771 | $103.92 | |
| 85007 | <1% | 1,876 | $96.89 | |
| A9270 | Non-covered item or service | <1% | 994 | $92.00 |
| 73110 | <1% | 406 | $87.07 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,341 | $79.81 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 407 | $77.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,963 | $74.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 401 | $73.33 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 696 | $70.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 764 | $63.73 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 631 | $53.87 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,125 | $48.61 |
| 80320 | <1% | 2,284 | $42.23 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,061 | $38.97 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 167 | $38.68 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,611 | $37.79 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,597 | $33.81 |
| 82553 | <1% | 606 | $32.11 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 561 | $29.83 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,781 | $28.57 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 903 | $26.61 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,470 | $25.75 |
| 86141 | <1% | 615 | $23.95 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,089 | $22.66 |
| 87210 | <1% | 1,265 | $20.34 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,237 | $17.84 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,841 | $16.72 |
| 84100 | <1% | 508 | $15.66 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,271 | $15.01 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,618 | $14.39 |
| 87081 | <1% | 137 | $14.22 | |
| 85652 | <1% | 336 | $11.64 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 168 | $10.90 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 74 | $7.74 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 764 | $5.57 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 132 | $5.17 |
| 87420 | <1% | 86 | $2.92 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 288 | $0.67 |
| 96367 | 0% | 53 | $0.00 | |
| 82009 | 0% | 161 | $0.00 | |
| 73080 | 0% | 87 | $0.00 | |
| 82272 | 0% | 73 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 118 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 462 | $0.00 |
| 73590 | 0% | 121 | $0.00 | |
| 82010 | 0% | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| 87634 | 0% | 106 | $0.00 | |
| 76937 | 0% | 58 | $0.00 | |
| 29125 | 0% | 16 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 18 | $0.00 |
| 36425 | 0% | 48 | $0.00 | |
| 97163 | 0% | 12 | $0.00 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 0% | 16 | $0.00 |
| 82140 | 0% | 23 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| 73502 | 0% | 148 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 13 | $0.00 |
| 82803 | 0% | 93 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 67 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 170 | $0.00 |
| 88342 | 0% | 32 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 45 | $0.00 |
| 86308 | 0% | 51 | $0.00 | |
| 83615 | 0% | 49 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 87 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 158 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 67 | $0.00 |
| 82728 | 0% | 17 | $0.00 | |
| C1769 | Guide wire | 0% | 45 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 84 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 26 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 16 | $0.00 |
| 72040 | 0% | 25 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 33 | $0.00 |
| 87581 | 0% | 13 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 63 | $0.00 |
| 87428 | 0% | 74 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 18 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 12 | $0.00 |
| 73090 | 0% | 15 | $0.00 | |
| 87486 | 0% | 13 | $0.00 | |
| 12002 | 0% | 13 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.